353 related articles for article (PubMed ID: 12501879)
1. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
[TBL] [Abstract][Full Text] [Related]
2. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study.
van Zyl L; le Roux JG; LaFata JA; Volk RS; Palo WA; Flamm R; Hom RC
Clin Ther; 2002 Nov; 24(11):1840-53. PubMed ID: 12501878
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
Poachanukoon O; Kitcharoensakkul M
Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections.
Bucko AD; Hunt BJ; Kidd SL; Hom R
Clin Ther; 2002 Jul; 24(7):1134-47. PubMed ID: 12182257
[TBL] [Abstract][Full Text] [Related]
10. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
Léophonte P; File T; Feldman C
Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia.
Higuera F; Hidalgo H; Feris J; Giguere G; Collins JJ
J Antimicrob Chemother; 1996 Mar; 37(3):555-64. PubMed ID: 9182112
[TBL] [Abstract][Full Text] [Related]
12. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children.
Hoberman A; Dagan R; Leibovitz E; Rosenblut A; Johnson CE; Huff A; Bandekar R; Wynne B
Pediatr Infect Dis J; 2005 Jun; 24(6):525-32. PubMed ID: 15933563
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.
Gwaltney JM; Savolainen S; Rivas P; Schenk P; Scheld WM; Sydnor A; Keyserling C; Leigh A; Tack KJ
Antimicrob Agents Chemother; 1997 Jul; 41(7):1517-20. PubMed ID: 9210677
[TBL] [Abstract][Full Text] [Related]
14. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
Garau J
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis.
Sher LD; McAdoo MA; Bettis RB; Turner MA; Li NF; Pierce PF
Clin Ther; 2002 Feb; 24(2):269-81. PubMed ID: 11911557
[TBL] [Abstract][Full Text] [Related]
17. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
File TM; Jacobs MR; Poole MD; Wynne B;
Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
20. Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study.
Riffer E; Spiller J; Palmer R; Shortridge V; Busman TA; Valdes J
Curr Med Res Opin; 2005 Jan; 21(1):61-70. PubMed ID: 15881476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
